Therapy Detail

Therapy Name Gemcitabine + Cisplatin
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cisplatin Platinol CDDP Chemotherapy - Platinum 6 Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).
Gemcitabine Gemzar Difluorodeoxycytidine Hydrochlorothiazide Chemotherapy - Antimetabolite 10 Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03682068 Phase III Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) Recruiting
NCT02453282 Phase III Durvalumab Gemcitabine + Cisplatin Paclitaxel + Carboplatin Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Active, not recruiting
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Gemcitabine + Cisplatin A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Recruiting
NCT02542293 Phase III Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab + Tremelimumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). Active, not recruiting
NCT02177695 Phase II Gemcitabine + Cisplatin Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Recruiting
NCT03267940 Phase I Gemcitabine + Cisplatin Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Active, not recruiting
NCT03656536 Phase III Pemigatinib Gemcitabine + Cisplatin A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting
NCT02567409 Phase II Gemcitabine + Cisplatin Cisplatin + Gemcitabine + VX-970 Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer Recruiting
NCT03875235 Phase III Gemcitabine + Cisplatin Cisplatin + Durvalumab + Gemcitabine A Global Phase III Study of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Not yet recruiting
NCT03036098 Phase III Gemcitabine + Cisplatin Nivolumab + Ipilimumab Carboplatin + Gemcitabine Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer Recruiting
NCT03403049 Phase I Gemcitabine + Cisplatin Capecitabine + Gemcitabine Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer Recruiting
NCT00942331 Phase III Gemcitabine + Bevacizumab + Cisplatin Gemcitabine + Cisplatin Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting
NCT03003962 Phase III Durvalumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Carboplatin + Pemetrexed Cisplatin + Pemetrexed Paclitaxel + Carboplatin Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer Active, not recruiting
NCT03773302 Phase III Gemcitabine + Cisplatin BGJ398 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting
NCT02452970 Phase II RRx-001 Gemcitabine + Cisplatin RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Active, not recruiting
NCT03661320 Phase III Cisplatin + Gemcitabine + Nivolumab Gemcitabine + Cisplatin BMS-986205 + Cisplatin + Gemcitabine + Nivolumab A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC Recruiting
NCT02537561 Phase I Talazoparib Gemcitabine + Cisplatin Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Carboplatin + Pemetrexed Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab Carboplatin + nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Recruiting
NCT01585805 Phase II Veliparib Gemcitabine + Cisplatin Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT03732677 Phase III Gemcitabine + Cisplatin Cisplatin + Durvalumab + Gemcitabine Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA) Recruiting
NCT02711553 Phase II Ramucirumab Merestinib Gemcitabine + Cisplatin A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT03425643 Phase III Cisplatin + Pemetrexed Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Gemcitabine + Cisplatin Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Recruiting
NCT02300610 Phase I Gemcitabine + Cisplatin Enzalutamide Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Active, not recruiting
NCT02128282 Phase Ib/II Gemcitabine + Cisplatin Cisplatin + Gemcitabine + Silmitasertib Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Recruiting